Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins

US5993827A · kind A · utility

Assignee

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

• Kim Lee Sim · Gaithersburg, US
• Chetan Chitnis · Washington, US
• Louis Miller · Bethesda, US
• David S. Peterson · Rockville, US
• Xin Su · Beijing, CN
• Thomas E. Wellems · Rockville, US

Key dates

• Filing date: Jun 7, 1995
• Grant date: Nov 30, 1999
• Expiry date: Jun 7, 2015

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides isolated polypeptides useful in the treatment and prevention of malaria caused by Plasmodium falciparum or P. vivax. In particular, the polypeptides are derived from the binding domains of the proteins in the DBL family as well as the sialic acid binding protein (SABP) on P. falciparum merozoites. The polypeptides may also be derived from the Duffy antigen binding protein (DABP) on P. vivax merozoites.